collection
https://read.qxmd.com/read/25383558/multitarget-therapy-for-induction-treatment-of-lupus-nephritis-a-randomized-trial
#21
RANDOMIZED CONTROLLED TRIAL
Zhihong Liu, Haitao Zhang, Zhangsuo Liu, Changying Xing, Ping Fu, Zhaohui Ni, Jianghua Chen, Hongli Lin, Fuyou Liu, Yongcheng He, Yani He, Lining Miao, Nan Chen, Ying Li, Yong Gu, Wei Shi, Weixin Hu, Zhengzhao Liu, Hao Bao, Caihong Zeng, Minlin Zhou
BACKGROUND: Treatment of lupus nephritis (LN) remains challenging. OBJECTIVE: To assess the efficacy and safety of a multitarget therapy consisting of tacrolimus, mycophenolate mofetil, and steroid compared with intravenous cyclophosphamide and steroid as induction therapy for LN. DESIGN: 24-week randomized, open-label, multicenter study. (ClinicalTrials.gov: NCT00876616). SETTING: 26 renal centers in China. PATIENTS: Adults (aged 18 to 65 years) with biopsy-proven LN...
January 6, 2015: Annals of Internal Medicine
https://read.qxmd.com/read/25185988/egf-receptor-deletion-in-podocytes-attenuates-diabetic-nephropathy
#22
JOURNAL ARTICLE
Jianchun Chen, Jian-Kang Chen, Raymond C Harris
The generation of reactive oxygen species (ROS), particularly superoxide, by damaged or dysfunctional mitochondria has been postulated to be an initiating event in the development of diabetes complications. The glomerulus is a primary site of diabetic injury, and podocyte injury is a classic hallmark of diabetic glomerular lesions. In streptozotocin-induced type 1 diabetes, podocyte-specific EGF receptor (EGFR) knockout mice (EGFR(podKO)) and their wild-type (WT) littermates had similar levels of hyperglycemia and polyuria, but EGFR(podKO) mice had significantly less albuminuria and less podocyte loss compared with WT diabetic mice...
May 2015: Journal of the American Society of Nephrology: JASN
https://read.qxmd.com/read/25107952/timing-of-rrt-based-on-the-presence-of-conventional-indications
#23
MULTICENTER STUDY
Suvi T Vaara, Matti Reinikainen, Ron Wald, Sean M Bagshaw, Ville Pettilä
BACKGROUND AND OBJECTIVES: No data on the development of conventional indications for RRT (refractory acidosis, hyperkalemia, uremia, oliguria/anuria, and volume overload) related to timing of RRT exist. The prevalence of conventional indications among critically ill patients on RRT for AKI was evaluated, and patients manifesting indications versus patients without indications were compared in terms of crude and adjusted 90-day mortality. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: In this substudy of the Finnish Acute Kidney Injury study conducted in 2011 and 2012 in 17 intensive care units with 2901 patients, patients were classified as pre-emptive (no conventional indications) and classic (one or more indications) RRT recipients...
September 5, 2014: Clinical Journal of the American Society of Nephrology: CJASN
https://read.qxmd.com/read/25114277/commentary-on-the-2014-bp-guidelines-from-the-panel-appointed-to-the-eighth-joint-national-committee-jnc-8
#24
COMMENT
Efrain Reisin, Raymond C Harris, Mahboob Rahman
The recently published article "2014 Evidence-based guideline for the management of high blood pressure in adults: Report from the panel members appointed to the Eighth Joint National Committee (JNC 8)" (James et al., JAMA 311: 507-520, 2014) has generated considerable controversy. In this commentary, we evaluate the document and compare the recommendations contained within it with those of the JNC 7 and other national and international guidelines. The evidence quality rating approach followed by the article "2014 Evidence-based guideline for the management of high blood pressure in adults: Report from the panel members appointed to the Eighth Joint National Committee (JNC 8)" (James et al...
November 2014: Journal of the American Society of Nephrology: JASN
https://read.qxmd.com/read/25016609/cell-cycle-arrest-and-the-evolution-of-chronic-kidney-disease-from-acute-kidney-injury
#25
REVIEW
Guillaume Canaud, Joseph V Bonventre
For several decades, acute kidney injury (AKI) was generally considered a reversible process leading to complete kidney recovery if the individual survived the acute illness. Recent evidence from epidemiologic studies and animal models, however, have highlighted that AKI can lead to the development of fibrosis and facilitate the progression of chronic renal failure. When kidney injury is mild and baseline function is normal, the repair process can be adaptive with few long-term consequences. When the injury is more severe, repeated, or to a kidney with underlying disease, the repair can be maladaptive and epithelial cell cycle arrest may play an important role in the development of fibrosis...
April 2015: Nephrology, Dialysis, Transplantation
https://read.qxmd.com/read/25035273/nephrotoxic-effects-of-common-and-emerging-drugs-of-abuse
#26
REVIEW
William F Pendergraft, Leal C Herlitz, Denyse Thornley-Brown, Mitchell Rosner, John L Niles
The kidneys can be injured in diverse ways by many drugs, both legal and illegal. Novel associations and descriptions of nephrotoxic effects of common and emerging drugs of abuse have appeared over the past several years. Anabolic androgenic steroids, illicitly used by athletes and others for decades to increase muscle mass and decrease body fat, are emerging as podocyte toxins given recent descriptions of severe forms of FSGS in long-term abusers. Synthetic cannabinoids, a new group of compounds with marijuana-like effects, recently became popular as recreational drugs and have been associated with an atypical form of AKI...
November 7, 2014: Clinical Journal of the American Society of Nephrology: CJASN
https://read.qxmd.com/read/23111824/age-and-association-of-kidney-measures-with-mortality-and-end-stage-renal-disease
#27
JOURNAL ARTICLE
Stein I Hallan, Kunihiro Matsushita, Yingying Sang, Bakhtawar K Mahmoodi, Corri Black, Areef Ishani, Nanne Kleefstra, David Naimark, Paul Roderick, Marcello Tonelli, Jack F M Wetzels, Brad C Astor, Ron T Gansevoort, Adeera Levin, Chi-Pang Wen, Josef Coresh
CONTEXT: Chronic kidney disease (CKD) is prevalent in older individuals, but the risk implications of low estimated glomerular filtration rate (eGFR) and high albuminuria across the full age range are controversial. OBJECTIVE: To evaluate possible effect modification (interaction) by age of the association of eGFR and albuminuria with clinical risk, examining both relative and absolute risks. DESIGN, SETTING, AND PARTICIPANTS: Individual-level meta-analysis including 2,051,244 participants from 33 general population or high-risk (of vascular disease) cohorts and 13 CKD cohorts from Asia, Australasia, Europe, and North/South America, conducted in 1972-2011 with a mean follow-up time of 5...
December 12, 2012: JAMA
https://read.qxmd.com/read/24206457/combined-angiotensin-inhibition-for-the-treatment-of-diabetic-nephropathy
#28
RANDOMIZED CONTROLLED TRIAL
Linda F Fried, Nicholas Emanuele, Jane H Zhang, Mary Brophy, Todd A Conner, William Duckworth, David J Leehey, Peter A McCullough, Theresa O'Connor, Paul M Palevsky, Robert F Reilly, Stephen L Seliger, Stuart R Warren, Suzanne Watnick, Peter Peduzzi, Peter Guarino
Combination therapy with angiotensin-converting-enzyme (ACE) inhibitors and angiotensin-receptor blockers (ARBs) decreases proteinuria; however, its safety and effect on the progression of kidney disease are uncertain. Methods We provided losartan (at a dose of 100 mg per day) to patients with type 2 diabetes, a urinary albumin-to-creatinine ratio (with albumin measured in milligrams and creatinine measured in grams) of at least 300, and an estimated glomerular filtration rate (GFR) of 30.0 to 89.9 ml per minute per 1...
November 14, 2013: New England Journal of Medicine
https://read.qxmd.com/read/25087196/progression-of-renal-injury-toward-interstitial-inflammation-and-glomerular-sclerosis-is-dependent-on-abnormal-protein-filtration
#29
REVIEW
Carlamaria Zoja, Mauro Abbate, Giuseppe Remuzzi
Chronic proteinuric renal diseases, independent from the type of the initial insult, have in common a loss of selectivity of the glomerular barrier to protein filtration. Glomerular sclerosis is the progressive lesion affecting the glomerular capillary wall, the primary site at which the protein filtration is abnormally enhanced by disease. Dysfunction of podocytes, that serve to maintain the intact barrier, is a central event in lesion development. However, glomerular injury is signalled to tubular and interstitial structures largely in advance of nephron destruction...
May 2015: Nephrology, Dialysis, Transplantation
https://read.qxmd.com/read/25097209/through-a-glass-darkly-seeking-clarity-in-preventing-late-kidney-transplant-failure
#30
REVIEW
Mark D Stegall, Robert S Gaston, Fernando G Cosio, Arthur Matas
A common lament is that long-term kidney transplant outcomes remain the same despite improvements in early graft survival. To be fair, progress has been made-in both our understanding of chronic injury and modestly, graft survival. However, we are still a long way from actually solving this important and difficult problem. In this review, we outline recent data supporting the existence of several causes of renal allograft loss, the incidences of which peak at different time points after transplantation. On the basis of this broadened concept of chronic renal allograft injury, we examine the challenges of clinical trial design in long-term studies, including the use of surrogate end points and biomarkers...
January 2015: Journal of the American Society of Nephrology: JASN
https://read.qxmd.com/read/25054778/a-closer-look-at-rituximab-induction-on-hla-antibody-rebound-following-hla-incompatible-kidney-transplantation
#31
JOURNAL ARTICLE
Annette M Jackson, Edward S Kraus, Babak J Orandi, Dorry L Segev, Robert A Montgomery, Andrea A Zachary
Rituximab has been used to increase the efficacy of desensitization protocols for human leukocyte antigen (HLA)-incompatible kidney transplantation; however, controlled comparisons have not been reported. Here we examined 256 post-transplant HLA antibody levels in 25 recipients desensitized with and 25 without rituximab induction, to determine the impact of B-cell depletion. We found significantly less HLA antibody rebound in the rituximab-treated patients (7% of donor-specific antibodies (DSAs) and 33% of non-DSAs) compared with a control cohort desensitized and transplanted without rituximab (32% DSAs and 55% non-DSAs)...
February 2015: Kidney International
https://read.qxmd.com/read/25047428/fluid-resuscitation-in-sepsis-a-systematic-review-and-network-meta-analysis
#32
REVIEW
Bram Rochwerg, Waleed Alhazzani, Anees Sindi, Diane Heels-Ansdell, Lehana Thabane, Alison Fox-Robichaud, Lawrence Mbuagbaw, Wojciech Szczeklik, Fayez Alshamsi, Sultan Altayyar, Wang-Chun Ip, Guowei Li, Michael Wang, Anna Wludarczyk, Qi Zhou, Gordon H Guyatt, Deborah J Cook, Roman Jaeschke, Djillali Annane
BACKGROUND: Fluid resuscitation is the cornerstone of sepsis treatment. However, whether balanced or unbalanced crystalloids or natural or synthetic colloids confer a survival advantage is unclear. PURPOSE: To examine the effect of different resuscitative fluids on mortality in patients with sepsis. DATA SOURCES: MEDLINE, EMBASE, ACP Journal Club, CINAHL, HealthSTAR, the Allied and Complementary Medicine Database, and the Cochrane Central Register of Controlled Trials through March 2014...
September 2, 2014: Annals of Internal Medicine
https://read.qxmd.com/read/20581422/a-randomized-controlled-trial-of-early-versus-late-initiation-of-dialysis
#33
RANDOMIZED CONTROLLED TRIAL
Bruce A Cooper, Pauline Branley, Liliana Bulfone, John F Collins, Jonathan C Craig, Margaret B Fraenkel, Anthony Harris, David W Johnson, Joan Kesselhut, Jing Jing Li, Grant Luxton, Andrew Pilmore, David J Tiller, David C Harris, Carol A Pollock
BACKGROUND: In clinical practice, there is considerable variation in the timing of the initiation of maintenance dialysis for patients with stage V chronic kidney disease, with a worldwide trend toward early initiation. In this study, conducted at 32 centers in Australia and New Zealand, we examined whether the timing of the initiation of maintenance dialysis influenced survival among patients with chronic kidney disease. METHODS: We randomly assigned patients 18 years of age or older with progressive chronic kidney disease and an estimated glomerular filtration rate (GFR) between 10...
August 12, 2010: New England Journal of Medicine
https://read.qxmd.com/read/23131078/ultrafiltration-in-decompensated-heart-failure-with-cardiorenal-syndrome
#34
RANDOMIZED CONTROLLED TRIAL
Bradley A Bart, Steven R Goldsmith, Kerry L Lee, Michael M Givertz, Christopher M O'Connor, David A Bull, Margaret M Redfield, Anita Deswal, Jean L Rouleau, Martin M LeWinter, Elizabeth O Ofili, Lynne W Stevenson, Marc J Semigran, G Michael Felker, Horng H Chen, Adrian F Hernandez, Kevin J Anstrom, Steven E McNulty, Eric J Velazquez, Jenny C Ibarra, Alice M Mascette, Eugene Braunwald
BACKGROUND: Ultrafiltration is an alternative strategy to diuretic therapy for the treatment of patients with acute decompensated heart failure. Little is known about the efficacy and safety of ultrafiltration in patients with acute decompensated heart failure complicated by persistent congestion and worsened renal function. METHODS: We randomly assigned a total of 188 patients with acute decompensated heart failure, worsened renal function, and persistent congestion to a strategy of stepped pharmacologic therapy (94 patients) or ultrafiltration (94 patients)...
December 13, 2012: New England Journal of Medicine
https://read.qxmd.com/read/23121377/tolvaptan-in-patients-with-autosomal-dominant-polycystic-kidney-disease
#35
RANDOMIZED CONTROLLED TRIAL
Vicente E Torres, Arlene B Chapman, Olivier Devuyst, Ron T Gansevoort, Jared J Grantham, Eiji Higashihara, Ronald D Perrone, Holly B Krasa, John Ouyang, Frank S Czerwiec
BACKGROUND: The course of autosomal dominant polycystic kidney disease (ADPKD) is often associated with pain, hypertension, and kidney failure. Preclinical studies indicated that vasopressin V(2)-receptor antagonists inhibit cyst growth and slow the decline of kidney function. METHODS: In this phase 3, multicenter, double-blind, placebo-controlled, 3-year trial, we randomly assigned 1445 patients, 18 to 50 years of age, who had ADPKD with a total kidney volume of 750 ml or more and an estimated creatinine clearance of 60 ml per minute or more, in a 2:1 ratio to receive tolvaptan, a V(2)-receptor antagonist, at the highest of three twice-daily dose regimens that the patient found tolerable, or placebo...
December 20, 2012: New England Journal of Medicine
https://read.qxmd.com/read/25007170/the-potential-for-renoprotection-with-incretin-based-drugs
#36
REVIEW
Tetsuhiro Tanaka, Yoshiki Higashijima, Takehiko Wada, Masaomi Nangaku
Incretin-based drugs, i.e., glucagon-like peptide-1 (GLP-1) receptor agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors, are widely used for the treatment of type 2 diabetes. In addition to the primary role of incretins in stimulating insulin secretion from pancreatic β-cells, they have extra pancreatic functions beyond glycemic control. Indeed, recent studies highlight the potential beneficial effects of incretin-based therapy in diabetic kidney disease (DKD). Experimental studies using various diabetic models suggest that incretins protect the vascular endothelium from injury by binding to GLP-1 receptors, thereby ameliorating oxidative stress and the local inflammatory response, which reduces albuminuria and inhibits glomerular sclerosis...
October 2014: Kidney International
https://read.qxmd.com/read/24322578/glucose-lowering-drugs-in-patients-with-chronic-kidney-disease-a-narrative-review-on-pharmacokinetic-properties
#37
REVIEW
Paul Arnouts, Davide Bolignano, Ionut Nistor, Henk Bilo, Luigi Gnudi, James Heaf, Wim van Biesen
The achievement of a good glycaemic control is one of the cornerstones for preventing and delaying progression of microvascular and macrovascular complications in patients with both diabetes and chronic kidney disease (CKD). As for other drugs, the presence of an impaired renal function may significantly affect pharmacokinetics of the majority of glucose-lowering agents, thus exposing diabetic CKD patients to a higher risk of side effects, mainly hypoglycaemic episodes. As a consequence, a reduction in dosing and/or frequency of administration is necessary to keep a satisfactory efficacy/safety profile...
July 2014: Nephrology, Dialysis, Transplantation
https://read.qxmd.com/read/23455173/biomarkers-in-nephrology-core-curriculum-2013
#38
REVIEW
Gearoid M McMahon, Sushrut S Waikar
No abstract text is available yet for this article.
July 2013: American Journal of Kidney Diseases
https://read.qxmd.com/read/19608703/bicarbonate-supplementation-slows-progression-of-ckd-and-improves-nutritional-status
#39
RANDOMIZED CONTROLLED TRIAL
Ione de Brito-Ashurst, Mira Varagunam, Martin J Raftery, Muhammad M Yaqoob
Bicarbonate supplementation preserves renal function in experimental chronic kidney disease (CKD), but whether the same benefit occurs in humans is unknown. Here, we randomly assigned 134 adult patients with CKD (creatinine clearance [CrCl] 15 to 30 ml/min per 1.73 m(2)) and serum bicarbonate 16 to 20 mmol/L to either supplementation with oral sodium bicarbonate or standard care for 2 yr. The primary end points were rate of CrCl decline, the proportion of patients with rapid decline of CrCl (>3 ml/min per 1...
September 2009: Journal of the American Society of Nephrology: JASN
https://read.qxmd.com/read/21804539/circulating-urokinase-receptor-as-a-cause-of-focal-segmental-glomerulosclerosis
#40
JOURNAL ARTICLE
Changli Wei, Shafic El Hindi, Jing Li, Alessia Fornoni, Nelson Goes, Junichiro Sageshima, Dony Maiguel, S Ananth Karumanchi, Hui-Kim Yap, Moin Saleem, Qingyin Zhang, Boris Nikolic, Abanti Chaudhuri, Pirouz Daftarian, Eduardo Salido, Armando Torres, Moro Salifu, Minnie M Sarwal, Franz Schaefer, Christian Morath, Vedat Schwenger, Martin Zeier, Vineet Gupta, David Roth, Maria Pia Rastaldi, George Burke, Phillip Ruiz, Jochen Reiser
Focal segmental glomerulosclerosis (FSGS) is a cause of proteinuric kidney disease, compromising both native and transplanted kidneys. Treatment is limited because of a complex pathogenesis, including unknown serum factors. Here we report that serum soluble urokinase receptor (suPAR) is elevated in two-thirds of subjects with primary FSGS, but not in people with other glomerular diseases. We further find that a higher concentration of suPAR before transplantation underlies an increased risk for recurrence of FSGS after transplantation...
July 31, 2011: Nature Medicine
label_collection
label_collection
2302
2
3
2014-07-11 04:12:08
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.